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Abstract
This chapter provides an overview of versatile and efficient chemical  syntheses of
vitamin  D  derivatives  by  application  of  either  linear  or  convergent  synthesis  ap‐
proaches. Synthesis of the most relevant naturally occurring vitamin D metabolites and
their  deuterated counterparts  to use as calibration and reference standards in LC‐
MS/MS assays is also shown. The chapter then summarizes the most important mass
spectrometric  approaches  to  quantify  important  vitamin  D  metabolites  in  human
biofluids. In addition, new developments are described that are aimed at the pathobio‐
logical interpretation of the measured vitamin D metabolite distributions in various
human diseases.
Keywords: vitamin D deficiency, biomarkers, low abundant vitamin D metabolites,
assay development, LC‐MS/MS, diagnosis, disease risk prediction
1. Introduction
Vitamin D is mostly known for its role in the regulation of calcium and phosphorous homeo‐
stasis [1–3]. Consequently, vitamin D deficiency may cause various disorders related to bone
mineralization [4].  Drugs based on vitamin D analogs are commonly used to treat bone
diseases (osteoporosis,  osteomalacia,  and rickets)  or psoriasis.  More recently,  it  has been
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suggested that vitamin D deficiency is also connected to a wide range of other diseases beyond
bone mineralization, such as diabetes, autoimmune diseases, cardiovascular diseases, and
cancer,  as  various  clinical  and  epidemiological  studies  have  shown [5–9].  However,  the
development of drugs for treatment of these diseases based on appropriate vitamin D analogs
has mostly failed, either due to their rapid metabolic clearance or their calcemic effects. Vitamin
D analogs are usually hormonally active compounds with pleiotropic functions and their
levels in the body are strictly regulated by the hormonal system. In cases of oversupply, they
are enzymatically degraded to avoid harmful effects such as calcemia, leading mainly to
inactivation  and  conversion  into  water  soluble  degradation  products  suitable  for  renal
clearance. Consequently, prevention of vitamin D deficiency rather than therapy of a vitamin
D‐related disease is a promising approach. Due to low concentration and short half‐life of the
active  metabolite,  1α,25‐dihydroxyvitamin  D3  (1,25(OH)2D3,  calcitriol)  (4)  in  serum,  the
biosynthetic precursor 25‐hydroxyvitamin D3 (25(OH)D3) (3) is usually measured as a marker
of vitamin D status. Additionally, more than 50 naturally occurring but low abundant vitamin
D metabolites of mostly unknown physiological  function have been identified. Common
assays, particularly ELISA and radio‐immunoassays (RIA), are often restricted to 25(OH)D3
because of sensitivity and specificity limitations [10–12]. Fortunately, recent mass spectrometry
advances have permitted reaching deeper into the metabolic cascade of vitamin D, including
low abundant species [13–17]. Consequently, a wide variety of naturally occurring metabolites
of potential biological activity can be analyzed simultaneously by liquid chromatography‐
tandem mass spectrometry (LC‐MS/MS), which is currently considered the “gold standard”
technique. However, this method has suffered in the past from the limited availability of the
required vitamin D metabolites needed as calibration and reference standards. Consequently,
as a prerequisite, all metabolites of interest have to be available for chemical synthesis, as
described in this chapter.
2. Metabolism of vitamin D
Vitamin D3 (2) is mainly synthesized in the skin from 7‐dehydrocholesterol (1) by UV irradi‐
ation and subsequent thermal isomerization of the intermediate product previtamin D3.
Vitamin D3 is then hydroxylated in the liver to 25(OH)D3 (3), followed by further oxidation in
the kidneys to 1,25(OH)2D3 (calcitriol) (4), which is usually considered the biologically active
metabolite (Scheme 1). Calcitriol 4 is metabolized via CYP24 to other oxidative products,
mainly 1α,24(R),25‐trihydroxyvitamin D3 (1,24,25(OH)3D3) (5), followed by subsequent
enzymatic oxidation and degradation of the carbon side chain to water soluble calcitroic acid
[1, 18] for final clearance from the body. 25(OH)D3 (3) is degraded in an analogous manner via
24(R),25‐dihydroxyvitamin D3 (24,25(OH)2D3) 6. Alternatively, 25(OH)D3 (3) and 1,25(OH)2D3
(4) can be metabolized to their corresponding 26,23‐lactones (7,8) [19]. Vitamin D metabolites
also have the potential to be metabolized through a C‐3 epimerization pathway, leading to C‐3‐
epi‐metabolites such as 9‐12, with an inversion of the stereogenic center at position C‐3 [20,
21]. These reactions lead to products that are believed to be inactive. Since high concentrations
of 3‐epi‐25‐hydroxyvitamin D3 (3‐epi‐25(OH)D3) (10) were found in infants [22], it was initially
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assumed that this pathway is only a consequence of an immature vitamin D metabolism. It
has also been shown, however, that the epimerization pathway is favored if, for any reason,
side chain degradation by CYP24 is inhibited [23].
Scheme 1. Metabolic pathways of vitamin D.
Finally, the corresponding metabolites of vitamin D2 (13) also have to be considered [18],
because food from plant origin (in particular mushrooms) and food supplements may contain
vitamin D2. Vitamin D2 metabolites have similar physiological function as compared to their
corresponding vitamin D3 analogs, although their potency is apparently lower [24]. A detailed
comparison of the metabolism of vitamin D2 and D3 [18] reveals that 25(OH)D3 (3) and
1,25(OH)2D3 (4) are preferentially metabolized at their side chains, particularly at C‐23, C‐24,
and C‐26, leading to metabolites susceptible to further oxidation, which is similar for vitamin
D2, even though there are slight differences as a consequence of the C‐22/23 carbon double
bond and a methyl group at C‐24. Thus, C‐24 hydroxylation of vitamin D2 may occur initially,
leading to 24‐hydroxyvitamin D2, following by C‐1 hydroxylation in the kidneys, giving 1,24‐
dihydroxyvitamin D2, which is subsequently oxidized in the side chain. Furthermore, 1,25‐
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dihydroxyvitamin D2, formed in an analogous manner to its D3 counterpart, may be
metabolized by side chain oxidation either to C‐1,24,25 or C‐1,25,26 trihydroxylated vitamin
D2, again followed by further side chain oxidation. Each of these both pathways again leads
to calcitroic acid as final metabolite.
3. Synthesis of low abundant vitamin D metabolites
The commercial unavailability of many relevant vitamin D3 and D2 species has limited the
scope of LC‐MS/MS assays in the past. For use as reference standards, vitamin D3 and D2
metabolites, as well as their corresponding stable isotopes (labeled with 2H (D) or 13C), have
to be synthesized by application of a versatile and cost‐effective methodology. A large variety
of chemical syntheses of vitamin D derivatives has been developed in the last few decades by
several academic and commercial groups [1, 25–27], mainly with the aim of synthesizing new
analogs for drug discovery and development purposes. These efforts have resulted in a large
number of more than 3000 synthesized compounds [28]. Critical evaluation of these methods
reveals, however, that only a few of them are suitable to reproducibly generate metabolites of
interest in gram quantities at reasonable costs within short time frames. In this chapter, we will
review some of the more suitable strategies that have been successfully applied and optimized
in our laboratory.
The synthesis of deuterated vitamin D3 and D2 metabolites is mostly accomplished using the
same procedures as those developed for nondeuterated metabolites.
The biosynthetic and technical synthesis (starting from an appropriate steroid precursor (an‐
alog to 1) is not favorable, due to low yields reached in the photochemical ring‐opening re‐
action. It usually fails if a 1‐hydroxy substituent is present. By far the most suitable methods
for synthesis of vitamin D3 and D2 metabolites start with readily available Vitamin D2 (13).
Two alternative strategies are applied, either by keeping the vitamin D skeleton intact dur‐
ing the course of the reaction sequence (linear synthesis) (Scheme 2), or by first cleaving the
molecule to obtain the A‐ring and the CD‐ring building block, and subsequently reconnect‐
ing both molecules after separate appropriate chemical modifications (convergent synthesis)
(Scheme 3) [1, 26, 27, 29, 30].
3.1. Linear synthesis of vitamin D metabolites
Following a linear synthesis (Scheme 2), the cis‐diene moiety of vitamin D2 (13) is protected
by sulfur dioxide after silylation of the hydroxyl group at C‐3 as a tert‐butyldimethylsilyl ether,
leading to the SO2 adduct 14. Labeling with deuterium at C‐6,19,19 can be carried out conven‐
iently by treatment with D2O or deuterated alcohol (e.g., isopropanol). Finally, thermal removal
of SO2 and photochemical isomerization leads to threefold deuterated vitamin D2 (d‐13). This
simple and convenient method to obtain C‐6,19,19 deuterated metabolites [31] can also be
applied to a wide variety of other vitamin D3 and D2 derivatives. In order to obtain metabolites
of the corresponding C‐3‐epi series of vitamin D3 or D2 metabolites, the configuration of the C‐3
OH group of vitamin D2 (13) can be epimerized under the so‐called “Mitsunobu conditions”
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[32], by treatment with an aromatic acid and an azodicarboxylate, resulting in the correspond‐
ing ester 15 with concomitant inversion of the stereogenic center at C‐3 (orientation of the
substituent has changed from β to α). The ester is finally cleaved by saponification with
potassium hydroxide or by reduction with lithium aluminum hydride to afford C‐3‐epi
vitamin D2 (16), which can be used to synthesize a wide variety of C‐3 epimers, including 3‐
epi‐25‐hydroxyvitamin D3 (3‐epi‐25(OH)D3) (10, d‐10) and 3‐epi‐1α,25‐dihydroxyvitamin D3 (3‐
epi‐1,25(OH)2D3) (11, d‐11). Yields are only moderate due to the favored formation of a
C‐3,4‐5,6‐7,8 all‐trans triene system by elimination. To further proceed with the synthesis, the
C‐22/23 double bond in the side chain of SO2 adduct 14 is cleaved by ozonolysis, leading to
alcohol 17 after reductive workup with sodium boronhydride, which can be used to add a
wide variety of modified side chains as appropriate. For instance, 17 can be converted to an
iodide, which is coupled in a nickel‐zinc‐mediated reaction with ethyl acrylate after prior
removal of the SO2 protective group to afford 18. At this stage, an allylic oxidation by selenium
dioxide can be carried out, leading to a 1α‐hydroxy series of metabolites, such as 19 as
appropriate precursor. Silylation of the newly generated hydroxyl group, followed by
Grignard reaction with methylmagnesium bromide, leads to 1α,25‐dihydroxy metabolites. If
a deuterated Grignard reagent, labeled with 3 deuterium atoms at their methyl groups, is
employed, the corresponding sixfold deuterium labeled metabolite is obtained, containing 3
deuterium atoms at C‐26 and C‐27, respectively. Finally, the C‐5/6 double bond has to be
isomerized photochemically, and the silyl protective groups have to be removed, ending up
with nondeuterated or deuterated 25(OH)D3 (3, d‐3) or 1,25(OH)2D3 (4, d‐4) [33], as shown in
Scheme 2. If 3‐epi‐vitamin D2 (16) is employed in this sequence, 3‐epi‐25(OH)2D3 (10, d‐10) is
obtained. 3‐epi‐1,25(OH)2D3 (11, d‐11) is obtained, if 1α‐hydroxylation by selenium dioxide
was carried out, and the resulting C‐1‐OH‐group is epimerized by oxidation and final
reduction.
Vitamin D2 metabolites are synthesized by application of analogous strategies as applied for
their corresponding D3 counterparts, although they are more challenging to synthesize, for
two reasons: vitamin D2 metabolites contain an olefinic double bond in C‐22/23‐position, which
has to be arranged in trans geometry during the course of a suitable coupling reaction of a CD‐
ring precursor and an alternated side chain building block by olefination. Most synthetic
olefination methods yield a mixture of cis and trans double bonds, leading to product mixtures
that are difficult to separate due to their similar polarity. If the reaction conditions are too basic,
C‐20 epimerization can also occur, leading to even more complex product mixtures. Addi‐
tionally, vitamin D2 metabolites contain a chiral methyl group in C‐24 position that has to be
ranged in a defined configuration. When a suitable building block bearing this methyl group
is employed in the synthesis, epimerization of the chiral center may occur under basic reaction
conditions, along with the risk for epimerization at C‐20 in the coupling reaction. Thus, alcohol
17 is converted to its corresponding phenylsulfone, which is coupled by olefination with
aldehyde 20, a method originally invented by Julia [34]. Note that 20 can be synthesized in a
few routine steps from commercially available (S)‐(+)‐3‐hydroxyisobutyric acid methyl ester,
which is submitted to a Grignard reaction with methyl‐magnesium bromide. Analogously to
the synthesis of the other sixfold deuterated metabolites labeled at C‐26/27, the addition of
deuterated Grignard reagent in the course of the reaction leads to sixfold deuterated vitamin
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D2 metabolites. Finally, the double bond at C‐5/6 of 21 has to be photochemically isomerized
and the silyl protective groups have to be removed, leading to nondeuterated or deuterated
25(OH)D2 (22, d‐22) [35].
Scheme 2. Linear synthesis of vitamin D metabolites. TBDMSCl: tert‐butyldimethylsilyl chloride, SO2: sulfur dioxide,
O3: ozone, NaBH4: sodium borohydride, iPrOD: deuterated isopropanol, Bu4NF: tetra‐n‐butylammonium fluoride,
NaHCO3: sodium hydrogen carbonate, TsCl: p‐toluenesulfonyl chloride, PhSH: thiophenol, MCPBA: 3‐chloroperben‐
zoic acid, I2: iodine, PCC: pyridinium chlorochromate, D3CMgBr: deuterated methylmagnesium bromide, SeO2: seleni‐
um dioxide, DIAD: diisopropyl azodicarboxylate, PPh3: triphenylphosphine, KOH: potassium hydroxide, LiAlH4:
lithium aluminium hydride.
3.2. Convergent synthesis of vitamin D metabolites
Alternatively, a convergent approach can be applied (Scheme 3), which is more versatile than
a linear synthesis and allows for more harsh reaction conditions and wider scope of suitable
substrates and reagents. In a classical and widely applied strategy, vitamin D2 (13) is submitted
to ozonolysis, leading to Inhoffen‐Lythgoe diol 23 and allylic alcohol 24 after reductive workup
with sodium boronhydride. After appropriate chemical modification of the CD‐ring precursor,
this compound is coupled with an A‐ring building block. Two strategies can be distinguished.
In the most common approach, invented by Lythgoe and further developed by the Hoffmann‐
La Roche group [36], allylic alcohol 24 is converted via an allylic chloride 25 in diphenylphos‐
phine oxide 26, which is coupled with a C‐8 ketone by a Wittig‐Horner olefination. The A‐ring
diphenylphosphine oxide 26 can be coupled before or after appropriate alteration of the side
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chain at the CD‐ring building block. To employ an A‐ring diphenylphosphine oxide such as
26 is favourable, if no further substituents except a C‐3 OH group and a C‐10 exo‐methylene
group in the A‐ring are needed, as it is already present in vitamin D2 (13). As example for an
efficient application of this strategy, the synthesis of 24,25(OH)2D3 (6) and its deuterated
counterpart (d‐6), their 3‐epi‐analogs (9/d‐9) and 1α‐analogs (5/d‐5), is shown in Scheme 3 [37].
Here, diol 23 is converted to its corresponding iodide, which is coupled with enone 27 (obtained
in a few routine steps from (R)‐(‐)‐lactic acid using a zinc‐copper‐catalyzed reaction mediated
by ultrasound, leading to 28. By Grignard reaction of 28 with nondeuterated or deuterated
methyl‐magnesium bromide, 29 or d‐29 are obtained. The 1,2‐diol moiety is protected as
isopropylidene ether, followed by oxidation with pyridinium chlorochromate to obtain ketone
30/d‐30, which can be coupled with diphenylphosphine oxide 26 to obtain d‐24,25(OH)2D3
(d‐6) after removal of silyl‐ and isopropylidene protective groups. To access the corresponding
C‐3‐epi‐analog, vitamin D2 is first bis‐hydroxylated at C‐7/8 using potassium permanganate.
Inversion of the stereogenic center at C‐3 under “Mitsunobu‐conditions” using picolinic acid
leads to the corresponding C‐3‐epi‐triol 31. The yields of this reaction are much higher as
compared to the synthesis of 16 used in the linear synthesis, because an elimination reaction
leading to a favored C‐3,4‐5,6‐7,8‐all‐trans system is avoided [38]. Silylation and cleavage of
the diol moiety of triol 31 by lead tetraacetate and reductive workup with sodium boronhy‐
dride lead to the CD‐ring fragment 32 and C‐3‐epi allylic alcohol 33, which can be used after
conversion to the corresponding diphenylphosphine oxide 34. Note that 34 is coupled to d‐30
to obtain d‐3‐epi‐24,25(OH)2D3 (d‐9) or its corresponding nondeuterated counterpart 9. 3‐epi‐
diphenylphosphine oxide 34 can be used as a versatile A‐ring building block to be employed
Scheme 3. Convergent synthesis of 24,25(OH)xD metabolites. TBDMSCl: tert‐butyldimethylsilyl chloride, O3: ozone,
NaBH4: sodium borohydride, I2: iodine, Cu: copper, Zn: zinc, D3CMgBr: deuterated methylmagnesium bromide,
Me2CO: acetone, PCC: pyridinium chlorochromate, KMnO4: potassium permanganate, DIAD: diisopropyl azodicar‐
boxylate, NCS: N‐chlorosuccinimide, LiPPh2: lithium diphenylphosphide, H2O2: hydrogen peroxide. BuLi: n‐butyllithi‐
um, Bu4NF: tetra‐n‐butylammonium fluoride, Pb(OAc)4: lead tetraacetate, SeO2: selenium dioxide.
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in a Wittig‐Horner reaction for the synthesis of a wide variety of 3‐epi vitamin D3 and D2
metabolites, by connection with appropriate CD‐ring building blocks with modified side chain,
as shown for the synthesis of 3‐epi‐24,25(OH)2D3 (9, d‐9) as representative example. Finally,
permanganate oxidation of vitamin D2 (13) leads to triol 35, which is converted in a few routine
steps, including a stereoselective 1α‐allylic oxidation with SeO2 via 36 to diphenylphosphine
oxide 37, which is then coupled with d‐30 to afford 1,24,25(OH)3D3 (5/d‐5).
Two other low abundant metabolites, 23(S),25(R)‐dihydroxyvitamin D3 26,23‐lactone 7 and
1α‐1,23(S),25(R)‐trihydroxyvitamin D3 26,23‐lactone 8, are synthesized in an analogous
manner [29] (Scheme 4), by coupling a CD‐ring ketone carrying an appropriate side chain with
diphenylphosphine oxide 26 or 37. Here CD‐ring‐building block 32 obtained from vitamin D2
13 is used, which is converted to aldehyde 38. In order to prepare an appropriate modified
side chain, isopentenol 39 is converted using a few routine steps to sulfone 40, which is then
coupled with 38 by a Julia olefination to afford 41. Removal of the isopropylidene protective
group, oxidation to an unsaturated α‐hydroxy carboxylic acid and subsequent iodolactoniza‐
tion leads to ketone 44 via 42 and 43, which is coupled with diphenylphosphine oxide 26 or
37, respectively, to give 7 and 8.
Scheme 4. Convergent synthesis of 23,26(OH)x‐lactone metabolites. TBDMSCl: tert‐butyldimethylsilyl chloride, O3:
ozone, LDA: lithium diisopropylamide, Na: sodium, Hg: mercury, PPTS: pyridinium p‐toluenesulfonate, DMSO: di‐
methyl sulfoxide, Py: pyridine, SO2: sulfur dioxide, I2: iodine, KOH: potassium hydroxide, Bu3SnH: tributyltin hydride,
Bu4NF: tetra‐n‐butylammonium fluoride, PCC: pyridinium chlorochromate, BuLi: n‐butyllithium.
3.3. Convergent Palladium-catalyzed synthesis of vitamin D metabolites
The A‐ring building block is preferably synthesized de novo, if further substituents apart from
a C‐3‐OH group and a C‐10 exo methylene group in the A‐ring (already present in vitamin
D2) are needed. This is particularly valuable for synthetic analogs containing substituents at
C‐2, which were developed in the past as new drugs [30]. However, natural metabolites may
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also contain additional substituents in the A‐ring, such as 4β,25‐dihydroxy vitamin D3 [39]. In
these cases, Pd catalyzed tandem reactions can be applied (Scheme 5). Initially invented by
Trost [40], an acyclic enyne 46 is coupled with a CD‐ring vinyl bromide 47 obtained by Peterson
olefination from the corresponding ketone. Closure of the A‐ring and its connection with CD‐
ring is preferably carried out in one pot. Alternatively, the corresponding triflate 48 can be
employed in a Zn‐mediated reaction, which was invented by Negishi [41]. Additionally, CD‐
ring alkene boranates 49 can be used via an analogous coupling method originally invented
by Suzuki [42]. Finally, a cyclic A‐ring enynes, such as 50, can be coupled with CD‐ring triflate
50, a coupling method invented by Sonogashira [43]. In all these cases, the CD‐ring vinyl
bromide 47, boranate 49, or triflate 51 are usually carrying the modified side chain already,
before coupling with the acyclic or cyclic A‐ring enyne. A major drawback of these methods
is the fact that synthesis of acyclic or cyclic enynes or other A‐ring building blocks not derived
from vitamin D2 involves many synthesis steps, and in some cases separation of diastereomeric
mixtures is also necessary to obtain enantiomerically and diastereomerically pure product.
However, the suitable starting materials can usually be obtained from the natural chiral pool
(i.e., terpenes such as carvone [44], malic acid [45], quinic acid [43], or carbon hydrates such as
D‐glucose [46] or D‐xylose [47]), which are usually readily available. A wide range of substrates
are tolerated. Consequently, these advanced strategies involving Pd catalyzed reactions have
widely been applied in recent years and are by now well established.
Scheme 5. Convergent Pd‐catalyzed synthesis of vitamin D metabolites via de novo‐A‐ring synthesis. Pd: palladium,
ZnCl2: zinc chloride.
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4. LC-MS/MS assays for vitamin D metabolites
In the second part of this chapter, an overview of the mass spectrometric analysis of vitamin
D metabolites in biological samples is presented. Because of the chemical nature of these
secosteroidal molecules, liquid chromatography‐tandem mass spectrometry (LC‐MS/MS)
currently provides the optimum analytical platform for analysis of vitamin D metabolites.
While mass spectrometry assays are often not as rugged and more expensive than most non‐
mass spectrometric assays (in particular immunoassays), they provide the ability to capture
multiple metabolites simultaneously at very low concentration levels. Immunoassays measure
the 25(OH)D3 and 25(OH)D2 metabolites only and have limitations with respect to detection
sensitivity as well as selectivity and specificity issues.
In most published assays, the metabolites are determined from serum or plasma matrices.
Other biological matrices have rarely been used, although vitamin D metabolites have
successfully been quantified in saliva [48] and various soft tissues [49]. In the following
sections, we discuss the requirements and characteristics of LC‐MS/MS of vitamin D metabo‐
lites; that is, chromatographic separation, ionization, m/z analysis, interferences and accuracy
issues, multimetabolite screening applications, and the clinical role of vitamin D fingerprinting
methods.
4.1. Liquid chromatographic separation of vitamin D metabolites
Due to the hydrophobic structure, vitamin D metabolites are generally easily separated on
reversed‐phase liquid chromatography stationary phases (e.g., octadecyl C18) materials
utilizing hydrophobic interactions. The vitamin D metabolites generally elute in the order
trihydroxylated < dihydroxylated < monohydroxylated metabolites, that is, for vitamin D3‐
related molecules, the order of chromatographic retention is 1,25(OH)2D3 < 25(OH)D3 < D3.
Between corresponding D2 and D3 analogs, the D2 metabolites elute marginally later than the
D3 versions. For the two important isomers of dihydroxylated vitamin D metabolites,
24,25(OH)2D3 and 1,25(OH)2D3, the order of retention is 24,25(OH)2D3 < 1,25(OH)2D3.
Possibly more interesting—from a chromatography point of view—are the biochemically
formed isomers after stereochemical reversal (β→α) at C‐3; for example, the epimers
25(OH)D3 and 3‐epi‐25(OH)D3. The subtle diastereomeric differences between these species
can be distinguished using specialized columns, such as combined C18/chiral [50], pentafluor‐
ophenyl (PFP) [51–53], and cyano (CN) [54–57].
4.2. Ionization of vitamin D metabolites for mass spectrometric analysis
Mass spectrometric determination of vitamin D metabolites using liquid chromatography‐
mass spectrometry (LC‐MS) is not trivial because of the structural limitations that the analytes
provide with respect to attaching a charge to the molecules. Gas chromatography‐mass
spectrometry techniques have been used in the past for qualitative analysis and structure
determinations, but these methods have been almost completely replaced by modern LC‐MS
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methods. While analysis of transformation products such as vitamin D sulfates is relatively
easy by LC‐MS as the metabolites can be simply analyzed as deprotonated molecules, ionizing
the relatively nonpolar vitamin D metabolites is not straightforward. For LC‐MS, electrospray
ionization (ESI) or atmospheric pressure chemical ionization (APCI) are the most common
ionization techniques, which usually result in the formation of [M+H]+ ions for most biological
molecules. APCI has been successfully applied to steroids, as gas‐phase chemical ionization
often efficiently transfers a proton to these types of molecules. ESI usually relies on a charging
mechanism in the liquid phase and one would therefore expect ESI to be less efficient than
APCI for vitamin D metabolites. In reality this is not the case, however, and both techniques
have equally been applied to vitamin D analysis, with the analytical figures of merit being
quite similar between the two ionization techniques. There appears to be a slight trend toward
application of ESI rather than APCI in recent years.
An important, often neglected consideration in the choice of ionization source is the (usually
detrimental) impact of coionized sample components that coelute with vitamin D metabolites
from the LC column. Here, ionization suppression effects caused by these coeluting molecules
may impact the outcome even stronger than the differences seen in ionization efficiencies
between ESI and APCI [58, 59]. However, no systematic comparison of ionization efficiency/
ionization suppression effects between ESI and APCI has been performed yet. Furthermore,
coionization of coeluting components also leads to the formation of isobaric interferences when
sample matrices such as plasma or serum are analyzed, which will be discussed in more detail
below.
Another useful ionization technique is atmospheric pressure photoionization (APPI). This
technique is very common in fields such as petroleum analysis, but surprisingly, it is virtually
unknown in the clinical community. To our knowledge, only one study has systematically
compared APPI with APCI and shown that APPI generated significantly higher ion currents
for 25(OH)D3 than APCI [60]. A second study applied APPI to quantification of 25(OH)D3
without comparison to ESI or APCI [61].
Finally, another option to overcome problems of ionization efficiency and resulting problems
with detection sensitivity is derivatization of vitamin D metabolites, to convert them into better
responding transformation products. Such procedures are now quite common in the vitamin
D analytical field; they comprise introduction of a chemical group that is readily ionized or is
permanently charged. Cookson‐type triazoline‐diones and triazoline‐dione‐related reagents
(e.g., 4‐phenyl‐1,2,4‐triazoline‐3,5‐dione [PTAD]) are most often applied, which utilize the
reaction of the reagent’s dienophile with the cis‐diene group at C‐5/C‐6 and C‐10/C‐19 of
vitamin D (Diels‐Alder [4+2] reaction) (Scheme 6).
Several promising PTAD assays have been described in the literature [39, 49, 62–64]. The
advantage of using the cis‐diene moiety is that all vitamin D metabolites contained in the
sample are converted when the reagent is present at sufficient concentrations (i.e., in large
excess quantities) as all relevant vitamin D metabolites possess this structural motif. Ionization
efficiency of 25(OH)D‐PTAD has been reported to be 100‐fold higher than the nonderivatized
molecules in ESI mode [65]. A structural variation in PTAD includes a permanently charged
quaternary ammonium moiety, which enhances detection sensitivity even further [66]. This
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reagent is commercially available. A recent chemotyping assay for multiple vitamin D
metabolites has shown detection limits in the fg/mL range for vitamin D metabolites from
human serum (see discussion below).
Scheme 6. Diels‐Alder [4+2] derivatization of vitamin D metabolites using PTAD.
4.3 Mass analyzers for vitamin D analysis
Most clinical applications for vitamin D utilize quadrupole‐based mass analyzers with low
resolving powers. Because these mass spectrometers measure m/z signals at “unit mass
resolution,” they cannot be operated in full scan mode for the accurate quantification of vitamin
metabolites when complex sample matrices such as serum are analyzed. Serum contains
multiple components of identical nominal molecular mass to vitamin D metabolites, several
of which have been shown to coelute during High Performance Liquid Chromatography
(HPLC) [67]. The coeluting metabolites then generate so‐called “isobaric” ions in the mass
spectra after ESI, which cannot be distinguished from the vitamin D target molecules using
low resolution MS. Therefore, tandem mass spectrometry (MS/MS) is implemented, which
activates the ionized species further and forces them to undergo collision‐induced dissociation
(CID) for generating structure‐specific product ions. The metabolite‐specific product ions are
then measured and their response used for quantification of the target metabolites.
By far the most common low resolution tandem mass spectrometer for vitamin D analysis in
clinical laboratories is the triple quadrupole (QqQ) instrument. In a QqQ mass spectrometer,
the [M+H]+ ions of vitamin D metabolites are selected in the first quadrupole, fragmented in a
quadrupole collision cell, and the products analyzed in the final quadrupole mass analyzer.
The acquisition mode that is almost always applied is the so‐called selected reaction monitor‐
ing (SRM) mode. In this mode, the [M+H]+ precursor ion is isolated in Q1 (e.g., m/z 401 for
25(OH)D3), dissociated in q2, and one specific product ion selected in Q3 (e.g., m/z 383). The
quality of the precursor/product ion selection determines the selectivity of analysis; that is, the
product ion structure should ideally directly reflect the chemical structure of the chosen
precursor ion for maximum specificity. For vitamin D metabolites, the selection of an appro‐
priate product ion is surprisingly difficult because of some inherent structural limitation of the
precursor structure, leading primarily to simple dehydration reactions at low collision
energies, which turn into complex mass spectra at higher collision energies (Figure 1) [68].
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Unfortunately, because of multiple, overlapping series of fragmentation reactions, leading to
“picket fence” type product ion spectra, fragment ions for vitamin D metabolites in the
diagnostic m/z range often resemble each other.
Figure 1. Collision-induced dissociation (CID) spectrum of the [M+H]+ ion of 1,25(OH)2D3 (spectrum after fully com-
pleted dehydration reactions after electrospray ionization and CID; m/z analysis by Fourier-transform ion cyclotron
resonance, FTICR).
A few studies also report the use of a low resolution quadrupole ion trap (IT) [69, 70] in
MS/MS mode for 25(OH)D3 and 25(OH)D2, but these instruments are rarely implemented in
clinical environments. IT instruments are often not fit for purpose for quantitation of low
abundant biological molecules, because of the large detrimental contributions of acquisition
time overhead to the duty cycle, thus limiting detection sensitivity. There is also a general
decline of this instrument type in modern mass spectrometry labs.
The most anticipated future development for vitamin D analysis is the introduction of high
resolution mass spectrometry (HRMS), which is now firmly established in many other fields
of modern mass spectrometry, in particular, in pharmaceutical applications and the proteomics
field [71]. This trend is mostly due to the availability of robust quadrupole-quadrupole-time-
of-flight (QqTOF) and orbitrap mass analyzers in recent years, which have transformed many
analytical approaches to mass spectrometry. The use of mass defect as metabolite-specific
property, for example, is now an integral part of many metabolite identification routines for
drug metabolites [72]. While the number of applications of HRMS in the vitamin D field is still
limited, the existing work has clearly demonstrated the potential of HRMS for vitamin D
analysis. For example, orbitrap mass spectrometers in full scan [73, 74] and MS/MS [75, 76]
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modes have been applied successfully to the analysis of 25(OH)D3 in human serum and
analytical performance has been shown to be equivalent or better than triple quadrupole and
immunoassays. The important role of HRMS in the separation of isobaric interferences will be
shown below.
4.4. Interferences during LC-MS/MS
The LC‐MS/MS analysis of vitamin D metabolites is affected by various sources of error, which
can affect both precision and accuracy. As with any other LC‐MS/MS analysis from biological
samples, ion suppression by coeluting sample components or chemical modifiers from the
sample preparation or chromatography can lead to reduced analyte signals. There are several
options to assess whether or not ion suppression is present, which have been summarized in
many review articles, e.g., by Matuszewski et al. [77]. Stable isotope standards of vitamin D
metabolites (mostly deuterated analogs) can usually correct for accuracy errors from ion
suppression effects, as long as it is guaranteed that protein binding for the isotope standard is
the same as for the endogenous analyte, which requires implementation of a careful incubation
routine [78]. Importantly, deuterated isotope standards are commercially available for most of
the relevant vitamin D metabolites but unfortunately not for all.
A second important source of analytical error originates from isobaric noise; that is, endoge‐
nous or exogenous metabolites that coelute with the vitamin D analytes and erroneously
contribute to the analytical signal, if unspecific ions are used for mass spectral analysis. This
has recently been described in detail by Qi et al. [67], who clearly demonstrated the presence
of multiple isobars of 25(OH)D3 in human serum. The isobars have to be carefully removed in
low resolution mass spectrometry, by application of appropriate MS/MS or ion mobility
spectrometry routines [67]. A number of exogenous and endogenous molecules have been
identified as relevant metabolites in serum samples [50, 67, 79].
Many of these interferences can be eliminated by application of high resolution mass spec‐
trometry using sufficiently high resolving powers; for example, through implementation of
orbitrap or Fourier‐transform ion cyclotron resonance (FTICR) mass spectrometers. For
example, Liebisch and Matysik demonstrated that the orbitrap MS instrument in their study
was able to separate an isobaric interference of 25(OH)D3 in the MS/MS domain; this interfer‐
ence was caused by fragmentation of the d6‐25(OH)D2 isotope standard [75].
Importantly, the issues relating to isobaric noise have only been studied for the 25(OH)D3
analyte; other metabolites will likely be affected by similar interferences, the impact of which
during quantification, in particular, in multimetabolite assays (see below), remains unknown.
4.5. Method accuracy and certified reference materials
The vitamin D analytical community is supported through the Vitamin D External Quality
Assessment Scheme (DEQAS), a nonprofit organization that evaluates the performance of
analytical assays of member laboratories for 25(OH)D3 and 1,25(OH)2D3 [80] through round‐
robin analyses. DEQAS has clearly demonstrated that analytical performance of vitamin D
analysis has greatly improved over the years between 1994 and 2009 [81].
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The United States National Institute of Standards and Technology (NIST) provides certified
standard solutions for 25(OH)D3 and 25(OH)D2. Furthermore, the NIST and the National
Institutes of Health (NIH) Office of Dietary Supplements (ODS) have established the Vitamin
D Metabolites Quality Assurance Program (VitDQAP), for interlaboratory comparison of
measurement of 25(OH)D2, 25(OH)D3, and 3‐epi‐25(OH)D3 in serum and plasma and provide
method‐appropriate control materials.
A number of commercial reference, calibration, and quality control materials are available from
several companies that allow rapid implementation and validation of vitamin D analytical
methodologies.
4.6. Vitamin D multimetabolite assays
One of the most important advantages of LC‐MS/MS assays over clinical immunoassays is the
ability to determine multiple vitamin D species independently and simultaneously. As a result,
there are now several very capable LC‐MS/MS assays described in the literature that provide
the capability for profiling the most relevant vitamin D metabolites at the same time, within a
single analytical run, and with sufficient dynamic range to allow measuring the required
physiological levels, down to the picomolar range. The topic has recently been reviewed in
detail and the interested reader is referred to Ref. [82]. Briefly, most of these multimetabolite
assays utilize derivatization techniques that transform all vitamin D species into better
responding analogs (vide supra). This procedure in turn permits analysis of both high and low
abundant vitamin D species with similar analytical figures of merit [62, 83].
The simultaneous acquisition of all important metabolite levels then provides the possibility
of using these vitamin D metabolite distributions (“chemotypes”) as complex diagnostic or
prognostic biomarkers for correlation with disease phenotype or clinical outcome of treatment.
A few examples for such correlations are summarized in the last section.
5. Vitamin D fingerprints (chemotypes) in clinical applications
A number of recent studies have gone beyond the usual determination of 25(OH)D3—as
marker for vitamin D status [84]—and 1,25(OH)2D3—for diagnosis of renal diseases, hyper‐
calcemic syndromes, and disorders of 25(OH)D3 metabolism [85]. These broader profiling
techniques are aimed at discovering dynamic effects of metabolites and catabolites, which are
located further downstream the 25(OH)D3 metabolic cascade. Current studies highlight
24,25(OH)2D3 as important diagnostic marker, which was previously only considered a
clearance product of vitamin D without activity. In fact, it has been shown that 24,25(OH)2D3
has crucial roles in bone metabolism [86] and renal diseases [87].
Capturing multiple vitamin D species and their dynamic changes allows for a better under‐
standing of interindividual variations after vitamin D supplementation. Müller et al. recently
demonstrated an inverse linear correlation between baseline 25(OH)D3 and response to
supplementation for patients with chronic liver disease [83]. The study also showed that lower
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baseline 24,25(OH)2D3 levels were linked to larger changes of 25(OH)D3 levels, and that those
patients who exhibited greater response to vitamin D supplementation had lower levels of 3‐
epi‐25(OH)D3 (Figure 2).
Berg et al. implemented the ratio of 24,25(OH)2D3 and 25(OH)D3 as a novel status marker for
vitamin D [88]. Wagner et al. used the same ratio and demonstrated that it was predictive of
25(OH)D3 response to supplementation [89]. Binkley et al. measured multiple vitamin D
species and developed a model to describe interindividual variation of 25(OH)D3 levels after
supplementation [90]; the authors highlighted the role of absorption (as measured by the
nonmetabolized vitamin D3 species) and degradation (via the 24,25(OH)2D3 species) and
presented a treat‐to‐target regime for tailored serum levels of 25(OH)D3 [90].
Figure 2. Nonparametric correlations between baseline vitamin D metabolites and response to vitamin D supplementa‐
tion for patients with chronic liver diseases after 6‐month treatment: (a) the relative change in serum 25(OH)D3 (in re‐
sponse to vitamin D supplementation) correlated inversely with baseline 25(OH)D3 concentrations; (b) similarly, an
inverse correlation between relative change in serum 25(OH)D3 and baseline 24,25(OH)2D3 was observed; (c) baseline
24,25(OH)2D3 concentrations were nonsignificantly higher in women as compared to men; (d) patients with lower 3‐
epi‐25(OH)D3 concentrations at baseline tended to have a larger response to vitamin D supplementation (reprinted
with permission from Ref. [83]).
Other important studies include the work by Bosworth et al. [87] and Stubs et al. [91], who
utilized multimetabolite LC‐MS/MS methods to characterize chronic kidney disease (CKD).
Similarly, Duan et al. [64] studied patients with multiple sclerosis and observed comparable
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levels of 25(OH)D3 in the healthy control subjects and the patients; however, serum levels for
1,25(OH)2D3 and 24,25(OH)2D3 were lower in patients than controls.
6. Conclusions
The availability of assays for simultaneous capturing multiple vitamin D metabolites com‐
bined with reliable techniques for synthesis of the required metabolite standard compounds
makes accurate measurement of metabolite distributions and subsequent correlation with
disease phenotype readily possible; the outcome of these strategies is expected to be useful for
diagnosis and risk prediction for various diseases. It may also allow for specific supplemen‐
tation strategies in the future, which consider patient‐specific dosage requirements and use of
selected vitamin D metabolites or analogs.
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